Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 9:56:100.
doi: 10.11606/s1518-8787.2022056004160. eCollection 2022.

Effect of ribociclib on productivity losses due to breast cancer in young women in Brazil

Anna Maria Buehler  1 , Pierre-Alexandre Dionne  2 , David Chandiwana  2 , Purnima Pathak  2 , Ebuwa Igho-Osagie  3
Affiliations

Effect of ribociclib on productivity losses due to breast cancer in young women in Brazil

Anna Maria Buehler et al. Rev Saude Publica. .

Abstract

Objetive: To evaluate the effect of ribociclib versus endocrine therapy on productivity losses due to advanced breast cancer.

Methods: Productivity data from the MONALEESA-7 trial, obtained from the results of the application of the Work Productivity and Activity Impairment (WPAI) questionnaire on progression-free survival state (43-month follow-up), were extrapolated to the 10,936 Brazilian prevalent cases of premenopausal women with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer. Productivity loss was determined by quantifying the economic costs of workforce dropout over time in both treatment arms and by discounting the economic costs of absenteeism and presenteeism from workforce retention. A human capital approach was used.

Results: Net productivity gains in the ribociclib arm were estimated at USD 4,285,525.00, representing 316,609 added work hours over 43 months and a mean of 2,009 added work weeks per year.

Conclusions: The phase III MONALEESA-7 trial productivity results applied to the Brazilian premenopausal prevalent cases of hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) breast cancer showed that treatment with ribociclib + endocrine therapy improves workforce participation compared with endocrine therapy alone in premenopausal women with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer, with potential economic gains for the Brazilian society.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors are collaborators of the company Novartis, manufacturer of the drug ribociclib.

References

    1. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global Cancer Observatory: cancer today. Lyon (FR): International Agency for Research on Cancer; 2020. [cited 2021 Dec 13]. Available from: https://gco.iarc.fr/today.
    1. Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321(3):288–300. doi: 10.1001/jama.2018.19323. - DOI - PubMed
    1. DeSantis CE, Bray F, Ferlay J, Lortet-Tieulent J, Anderson BO, Jemal A. International variation in female breast cancer incidence and mortality rates. Cancer Epidemiol Biomarkers Prev. 2015;24(10):1495–1506. doi: 10.1158/1055-9965.EPI-15-0535. - DOI - PubMed
    1. O’Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005;10(Suppl 3):20–29. doi: 10.1634/theoncologist.10-90003-20. - DOI - PubMed
    1. Axelrod D, Smith J, Kornreich D, Grinstead E, Singh B, Cangiarella J, et al. Breast cancer in young women. J Am Coll Surg. 2008;206(6):1193–1203. doi: 10.1016/j.jamcollsurg.2007.12.026. - DOI - PubMed

LinkOut - more resources